(19)
(11) EP 2 544 767 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
05.06.2019 Bulletin 2019/23

(45) Mention of the grant of the patent:
19.12.2018 Bulletin 2018/51

(21) Application number: 11753716.7

(22) Date of filing: 09.03.2011
(51) International Patent Classification (IPC): 
A61N 7/00(2006.01)
 A61N 7/02(2006.01)
(86) International application number:
PCT/US2011/000436
(87) International publication number:
WO 2011/112250 (15.09.2011 Gazette 2011/37)

(54)

ULTRASONIC THERAPY APPLICATOR

ULTRASCHALLTHERAPIEAPPLIKATOR

APPLICATEUR DE THÉRAPIE ULTRASONORE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 09.03.2010 US 311847 P

(43) Date of publication of application:
16.01.2013 Bulletin 2013/03

(73) Proprietor: Profound Medical Inc.
Mississauga, ON L4W 5K5 (CA)

(72) Inventors:
  • CHOPRA, Rajiv
    Mississauga, ON L4W 5K5 (CA)
  • DONALDSON, Sean
    Mississauga, ON L4W 5K5 (CA)
  • MAHON, Cameron
    Mississauga, ON L4W 5K5 (CA)

(74) Representative: DTS Patent- und Rechtsanwälte Schnekenbühl und Partner mbB 
Marstallstrasse 8
80539 München
80539 München (DE)


(56) References cited: : 
US-A- 5 593 415
US-A- 6 077 257
US-A1- 2006 206 105
 US-A- 5 593 415
US-A1- 2002 087 156
US-A1- 2006 206 105
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).